One architecture. Every platform.
The stack was designed for regulated data from the start. Validated inputs, traceable reasoning, and auditable outputs are not features added after the fact. They are how the system is built, which is why compliance behaves the same way across every module.
Compliance is a property of the architecture, not a feature on top of it.
Most AI tools in life sciences fail at the same point. The model works, the pilot succeeds, and then the system cannot be validated, so it never reaches a regulated function.
Provenance cannot be added to data after the fact. Once a value has been copied between systems without its lineage, the only honest answer to where it came from is an investigation. The governed data layer therefore records origin, transformation, and authority at the moment of ingestion, across omics streams, clinical trial data, real world evidence, regulatory submissions, electronic health records, and biobank material.
Industry research repeatedly finds data readiness rather than model quality to be the blocker. Surveys of drug manufacturers have reported that a large majority consider their own data unready for AI, and that most abandoned AI initiatives were abandoned over data quality and fragmentation rather than over model performance.
Reasoning runs through validated inference pipelines with explainability as a required output rather than an optional view. Retrieval is constrained to trusted sources, so the system declines when the evidence is absent instead of generating something plausible. Human review is retained at the decision point, not offered as an afterthought.
Model orchestration is deliberately vendor agnostic. No single model provider holds the reasoning behind a scientific conclusion, which matters both for continuity and for the awkward question of what happens when a provider changes a model underneath a validated system.
Output is built to be read by a reviewer as much as by the scientist who asked the question. Every result carries an attributable, timestamped, immutable record of the path that produced it, aligned to 21 CFR Part 11 expectations and to ALCOA+ principles. Deployment is API first, so the audit trail travels with the output into whatever system consumes it.
In January 2025 the FDA issued draft guidance on the use of artificial intelligence to support regulatory decision-making for drug and biological products. It proposes a risk-based credibility assessment framework in which credibility is established for a specific context of use rather than for a model in general, and it applies across nonclinical, clinical, post-marketing, and manufacturing phases. Drug discovery sits outside its scope.
That framework is the design brief. Stating a context of use, assessing model risk against it, and assembling the supporting evidence as the work is done rather than afterward is the difference between a system that can be validated and one that cannot.